154 related articles for article (PubMed ID: 20511183)
1. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.
Beauchesne P; Bernier V; Carnin C; Taillandier L; Djabri M; Martin L; Michel X; Maire JP; Khalil T; Kerr C; Gorlia T; Stupp R; Pedeux R
Neuro Oncol; 2010 Jun; 12(6):595-602. PubMed ID: 20511183
[TBL] [Abstract][Full Text] [Related]
2. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
[TBL] [Abstract][Full Text] [Related]
3. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
5. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
7. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
[TBL] [Abstract][Full Text] [Related]
8. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
10. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
15. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
16. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
17. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.
Elinzano H; Glantz M; Mrugala M; Kesari S; Piccioni DE; Kim L; Pan E; Yunus S; Coyle T; Timothy K; Evans D; Mantripragada K; Boxerman J; DiPetrillo T; Donahue JE; Hebda N; Mitchell KM; Rosati KL; Safran H
Am J Clin Oncol; 2018 Feb; 41(2):159-162. PubMed ID: 26658237
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.
Floyd NS; Woo SY; Teh BS; Prado C; Mai WY; Trask T; Gildenberg PL; Holoye P; Augspurger ME; Carpenter LS; Lu HH; Chiu JK; Grant WH; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):721-6. PubMed ID: 14967426
[TBL] [Abstract][Full Text] [Related]
19. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.
Wakabayashi T; Natsume A; Mizusawa J; Katayama H; Fukuda H; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S;
J Neurooncol; 2018 Jul; 138(3):627-636. PubMed ID: 29557060
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
